← Back to Screener
Enlivex Ltd. Ordinary Shares (ENLV)
Price$0.88
Favorite Metrics
Price vs S&P 500 (26W)-34.01%
Price vs S&P 500 (4W)-25.23%
Market Capitalization$204.03M
All Metrics
Book Value / Share (Quarterly)$0.72
P/TBV (Annual)0.60x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.49
Price vs S&P 500 (YTD)18.12%
EPS (TTM)$-0.55
10-Day Avg Trading Volume0.75M
EPS Excl Extra (TTM)$-0.55
EPS (Annual)$-0.73
ROI (Annual)-63.65%
Cash / Share (Quarterly)$0.75
ROA (Last FY)-54.23%
EBITD / Share (TTM)$-0.61
ROE (5Y Avg)-53.05%
Cash Flow / Share (Annual)$-0.55
P/B Ratio11.67x
P/B Ratio (Quarterly)1.45x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)-4.92x
ROA (TTM)-53.33%
EPS Incl Extra (Annual)$-0.73
Current Ratio (Annual)6.84x
Quick Ratio (Quarterly)6.04x
3-Month Avg Trading Volume0.60M
52-Week Price Return-0.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.72
52-Week High$2.10
EPS Excl Extra (Annual)$-0.73
CapEx CAGR (5Y)-11.53%
Tangible BV CAGR (5Y)78.21%
26-Week Price Return-25.26%
Quick Ratio (Annual)6.27x
13-Week Price Return-11.12%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.43x
Enterprise Value$199.946
Book Value / Share Growth (5Y)0.96%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.99
3-Month Return Std Dev84.76%
Net Income / Employee (TTM)$-0
ROE (Last FY)-63.65%
Net Interest Coverage (Annual)-19.36x
EPS Basic Excl Extra (Annual)$-0.73
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.55
ROI (TTM)-62.91%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.09
Price vs S&P 500 (52W)-35.15%
Year-to-Date Return22.26%
5-Day Price Return2.54%
EPS Normalized (Annual)$-0.73
ROA (5Y Avg)-44.71%
Month-to-Date Return-7.58%
Cash Flow / Share (TTM)$-1.59
EBITD / Share (Annual)$-0.75
ROI (5Y Avg)-53.05%
EPS Basic Excl Extra (TTM)$-0.55
P/TBV (Quarterly)0.67x
P/B Ratio (Annual)1.09x
Book Value / Share (Annual)$1.00
Price vs S&P 500 (13W)-13.98%
Beta1.55x
Revenue / Share (TTM)$0.00
ROE (TTM)-62.91%
52-Week Low$0.66
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ENLVEnlivex Ltd. Ordinary Shares | — | — | — | — | $0.88 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Enlivex Ltd is a clinical-stage immunotherapy company developing Allocetra, a macrophage reprogramming therapy for osteoarthritis currently in late-stage clinical development. The company's platform leverages immune cell reprogramming technology to address degenerative joint disease.